SCHEMBL256750

SCHEMBL256750

CC(=O)Nc1cc(C(=O)O)ccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4D Q6B0I6 4/20 0.54
KDM4C Q9H3R0 6/20 0.54
KDM3A Q9Y4C1 4/20 0.54
KDM5A P29375 3/20 0.54
KDM5B Q9UGL1 3/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
KDM4E B2RXH2 4/20 0.52
KDM6B O15054 3/20 0.52
KDM5C P41229 3/20 0.52
KDM2A Q9Y2K7 3/20 0.52
KDM4A O75164 2/20 0.52
TET3 O43151 1/20 0.52
BBOX1 O75936 1/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
ASPH Q12797 1/20 0.52
TET2 Q6N021 1/20 0.52
ALKBH5 Q6P6C2 1/20 0.52
KDM7A Q6ZMT4 1/20 0.52
KDM8 Q8N371 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10264295 0.87 L3MBTL1 (0.55) KDM4DKDM4CKDM3AKDM5AKDM5B
SCHEMBL25188111 0.84 L3MBTL1 (0.52) L3MBTL1PIK3C3JAK2JAK1TYK2
SCHEMBL8092962 0.84 L3MBTL1 (0.52) L3MBTL1PIK3C3JAK2JAK1TYK2
SCHEMBL16264542 0.83 KDM4C (0.55) KDM4DKDM4CKDM3AKDM5AKDM5B
SCHEMBL19736346 0.83 PIP5K1C (0.56) L3MBTL1MAPTPIK3C3JAK2JAK1
SCHEMBL2309698 0.83 KDM4E (0.55) KDM4CKDM3AL3MBTL1KDM4EKDM6B
SCHEMBL31095588 0.83 KDM4E (0.55) KDM4CKDM3AL3MBTL1KDM4EKDM6B
SCHEMBL5542919 0.82 PIK3C3 (0.57) PIK3C3PIP5K1CPIK3CA
SCHEMBL26185631 0.82 NR3C2 (0.56) KDM4DKDM4CKDM3AKDM5AKDM5B
SCHEMBL1759068 0.81 KDM4D (0.57) KDM4DKDM4CKDM3AKDM5AKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12110287-B2 Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2024-10-08 US disclosed
CN-112047928-B Isonicotinamide AChE-GSK3 double inhibitor and preparation method and application thereof 中国药科大学 2022-09-23 CN disclosed
US-20220048892-A1 HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC. (JP) 2022-02-17 US disclosed
EP-3902544-A1 HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RaQualia Pharma Inc. (JP) 2021-11-03 EP disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
CN-113164461-A Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2021-07-23 CN disclosed
EP-3782997-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES Galapagos N.V. (BE) 2021-02-24 EP disclosed
US-20210040062-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2021-02-11 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-112047928-A Isonicotinamide AChE-GSK3 double inhibitor and preparation method and application thereof 中国药科大学 2020-12-08 CN disclosed
CN-1242773-A Ticyclic carbapenem compound GLAXO WELLCOME SPA (IT) 2000-01-26 CN disclosed
US-5972975-A Substituted 2-aminopyridines as inhibitors of nitric oxide synthase MERCK & CO., INC. (US) 1999-10-26 US disclosed
EP-0937078-A1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXO WELLCOME S.p.A. (IT) 1999-08-25 EP disclosed
CN-1209060-A Vitronectin receptor antagonists SMITHKLINE BEECHAM CORP (US) 1999-02-24 CN disclosed
EP-0895475-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-10 EP disclosed
WO-1998021210-A1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXO WELLCOME S.P.A. (IT) 1998-05-22 WO disclosed
WO-1997024122-A1 VITRONECTIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-10 WO disclosed
WO-1996018616-A1 SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO., INC. (US) 1996-06-20 WO disclosed
EP-0674623-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1995-10-04 EP disclosed
WO-1994014776-A2 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12110287-B2 Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A KDM4D 3052/4885KDM4C 2659/4885KDM3A 3046/4885
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A KDM4D 1798/4885KDM4C 2040/4885KDM3A 1969/4885
US-20220048892-A1 HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS SCN8A, SCN7A, SCN1A KDM4D 3052/4885KDM4C 2659/4885KDM3A 3046/4885
US-20210040062-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND CYP2F1, CYP21A2, CYP11B1 KDM4D 335/4885KDM4C 324/4885KDM3A 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.